Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno-Associated, Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others),  By Grade (GMP Grade and R&D Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics) By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 635.1 Mn in 2021 and is expected to exhibit a CAGR of 23.2% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Increasing number of patients opting for gene therapy is expected to drive the global plasmid DNA manufacturing market growth over the forecast period. For instance, according to the data published by the Journal of Gene Medicine: March 2018, till November 2017, an estimated 2,600 gene therapy clinical trials were either ongoing, completed, or have been approved in 36 countries. Countries where the trials were conducted include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, severe combined immunodeficiency (SCID), ocular diseases, neurological diseases, and others.

Global Plasmid DNA Manufacturing Market – Impact of Coronavirus (COVID-19) Pandemic on Clinical Trials and Drug Development

Number of COVID-19 infections have been rising globally, with this the apprehension regarding the shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. Moreover, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients who may require critical care. Currently, there is an urgent need in the rapid acceleration of the manufacturing process to develop a wide range of test-kits (antibody tests, self-administered, and others). Key players operating in the market are focusing on the development of DNA vaccines for the treatment of COVID-19. In April 2020, INOVIO pharmaceuticals Inc. entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which is currently in Phase 1 clinical testing in the U.S. for COVID-19 treatment and could potentially advance to Phase 2/3 efficacy trials this summer April 2020. Increasing government initiatives to combat COVID-19 will help recover the pandemic situation early. For instance, in March 2020, the U.S. announced a US$ 2.9 million assistance package for India to help the Indian government prepare laboratory systems, activate case-finding and event-based surveillance, and support technical experts for response and preparedness. This is a part of the U.S. global assistance initiative to fight COVID -19.

Browse 44 Market Data Tables and 46 Figures spread through 266 Pages and in-depth TOC on “Global Plasmid DNA Manufacturing Market ”- Forecast to 2028, Global Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno Associated, and Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others),  By Grade (GMP Grade and R&D Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), By Development Phase (Pre- Clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics) By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

https://www.coherentmarketinsights.com/market-insight/plasmid-dna-manufacturing-market-2593

Key players are focusing on various inorganic growth strategies such as collaborations, this is expected to boost the growth of the Global Plasmid DNA Manufacturing Market over the forecast period. For instance, in May 2018, Biomay, CDMO and BIA Separations, a leading biochromatography development and manufacturing company, entered into a collaboration agreement in order to co-develop an economical production system for the production and purification of large DNA plasmids.

Key Takeaways of the Global Plasmid DNA Manufacturing Market:

  • The Global Plasmid DNA Manufacturing Market is expected to exhibit a CAGR of 23.2% during the forecast period owing to increasing adoption of inorganic growth strategies such as partnership by key players operating in the market, which is expected to drive growth of the global plasmid DNA manufacturing market over the forecast period. For instance, in June 2017, Alma Bio Therapeutics SAS (Alma) and Delphi Genetics extended their strategic alliance (partnership) to develop plasmid DNA drugs. Under this alliance, Delphi Genetics produced Plasmid DNA for Alma Bio Therapeutics SAS pipeline .
  • On the basis of Product Type, Plasmid DNA segment is estimated to exhibit a higher CAGR in the Global Plasmid DNA Manufacturing Market over forecast period. For instance, Cobra Biologics has been manufacturing pDNA for various clinical applications in the U.K. under the European Union (EU) clinical trials directive. The company has developed its own manufacturing process for purification and production of pDNA with related technologies including cell-lysis technologies, operator repressor titration (ORT), and an antibiotic-free plasmid maintenance system.
  • In terms of Development Phase, Pre-clinical Therapeutics is estimated to hold a dominant position in the Global Plasmid DNA Manufacturing Market in 2021. The increasing research and development activities for the development of novel plasmid DNA is expected to drive the segment growth over the forecast period. For instance, in October 2018, Applied DNA Sciences Inc., the leader in largescale Polymerise Chain Reaction -based DNA manufacturing, announced that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, had initiated pre-clinical development of a non-viral, plasmid-free (NVPF) chimeric antigen receptor (CAR) modified T cell (CAR T) manufacturing platform which is available to CAR-T developers worldwide.
  • Among the regions, North America is expected to hold dominant position in the Global Plasmid DNA Manufacturing Market in 2021. North America is expected to witness significant market growth owing to the presence of key players in the region who are focused on facility expansions to increase production and research & development activities. For instance, in November 2018, VGXI Inc. announced the opening of a new facility to expand its bio-manufacturing services, which includes space for flexible scale plasmid DNA manufacturing as well as purpose built GMP production areas for RNA synthesis.
  • Major players operating in the Global Plasmid DNA Manufacturing Market are Cobra Biologics and Pharmaceutical Services*, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Waisman Biomanufacturing, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, Genscript Biotech Corporation, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., Cepham Life Sciences, Delphi Genetics, Biomiga, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd, Luina Bio Pty Ltd, Ajinomoto Bio-Pharma Services, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., and Geneone Life Science
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner